## Abstract Neuropsychiatric symptoms are frequent in dementia with Lewy bodies (DLB). Dopamine transporter (DAT) imaging with ^123^I‐labeled ligand __N__‐δ‐(fluoropropyl)‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)tropene (^123^I‐FP‐CIT), which reliably measures midbrain dopaminergic dysfunction, has provid
Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using123I-FP-CIT SPECT
✍ Scribed by Sean J. Colloby; E. David Williams; David J. Burn; Jim J. Lloyd; Ian G. McKeith; John T. O’Brien
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 213 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objectives To compare the frequency and clinical correlates of neuropsychiatric symptoms in patients with Parkinson's disease (PD) with and without dementia and in those with dementia with Lewy bodies (DLB). ## Methods Neuropsychiatric symptoms during the month prior to assessment
## Abstract Risk factors predicting an increased risk of dementia in Parkinson's disease (PD) are not fully established. The dementia associated with PD (PDD) closely resembles dementia with Lewy bodies (DLB). Based upon a high frequency of non‐dopaminergic mediated clinical features in DLB, we pre
## Abstract ## Background Little is known about the rate of progression or associations of cognitive impairment in dementia with Lewy bodies (DLB), or the associations of accelerated decline. ## Method Dementia patients from a case register were evaluated at baseline and 1 year follow‐up using t